Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06259162
NA

LAG3 Expression in Triple Negative Breast Cancer

Sponsor: Samsung Medical Center

View on ClinicalTrials.gov

Summary

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Official title: The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer

Key Details

Gender

FEMALE

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

128

Start Date

2022-11-18

Completion Date

2027-12-31

Last Updated

2024-02-14

Healthy Volunteers

Yes

Interventions

PROCEDURE

LAG-3 expression / immune checkpoint protein expression

Evaluate the tissue and blood before and after chemotherapy

Locations (1)

Ji-Yeon Kim

Seoul, South Korea